Respiratory syncytial virus (RSV) poses great health threats to humans. However, there are no licensed vaccines or therapeutic drugs to date. Only one humanized monoclonal antibody, palivizumab, is available on the market, but it is used prophylactically and is limited to infants under high risk. With advances in antibody engineering, it has been found that single domain antibody (sdAb) can be therapeutically administered by inhalation, which would be more efficient for respiratory diseases. Here, we identified two human sdAbs, m17 and m35, by phage display technology. They specifically bind to RSV F in the prefusion state with subnanomolar affinity and potently neutralize both RSV subtypes A and B with IC
50
values ranging from pM to nM. Interestingly, these sdAbs recognize a novel epitope termed VI that is unique to the prefusion state. This epitope is located at the C-terminus of the F1 subunit, close to the viral membrane, and might be sterically restricted. We further find that m17 and m35 neutralize RSV by preventing the prefusion F conformational arrangement, thus inhibiting membrane fusion. These two sdAbs have the potential to be further developed as therapeutic candidates, and may also provide novel insight for developing other antiviral reagents against RSV.
Importance
Because RSV can cause serious respiratory disease in immunodeficient groups, including infants and seniors, the development of vaccines and therapeutic drugs, like neutralizing antibodies, is urgently needed. Compared to the conventional full-length antibody, single domain antibody (sdAb) has been demonstrated to be efficient for respiratory diseases when administered by inhalation, thereby potentially introducing a kind of novel therapeutic agent in the market. Here, we discovered two potent neutralizing human sdAbs against RSV that recognized a novel prefusion epitope termed VI and prevented conformational arrangement during the fusion process. Our work provides not only therapeutic candidates but also novel target for new drug and vaccine development.
Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody
